Egetis Therapeutics AB (publ)

SSE:EGTX.ST

6.07 (SEK) • At close February 20, 2024
Bedrijfsnaam Egetis Therapeutics AB (publ)
Symbool EGTX.ST
Munteenheid SEK
Prijs 6.07
Beurswaarde 1,775,905,970
Dividendpercentage 0%
52-weken bereik 3.8 - 9.2
Industrie Biotechnology
Sector Healthcare
CEO Mr. Nicklas Westerholm
Website https://www.egetis.com

An error occurred while fetching data.

Over Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning,

Vergelijkbare Aandelen

Episurf Medical AB (publ) logo

Episurf Medical AB (publ)

EPIS-B.ST

0.98 SEK

Stille AB logo

Stille AB

STIL.ST

160.5 SEK

FluoGuide A/S logo

FluoGuide A/S

FLUO.ST

55.6 SEK

Oncopeptides AB (publ) logo

Oncopeptides AB (publ)

ONCO.ST

7.264 SEK

InDex Pharmaceuticals Holding AB (publ) logo

InDex Pharmaceuticals Holding AB (publ)

INDEX.ST

0.244 SEK

Enzymatica AB (publ) logo

Enzymatica AB (publ)

ENZY.ST

3.05 SEK

Karolinska Development AB (publ) logo

Karolinska Development AB (publ)

KDEV.ST

1.65 SEK

Boule Diagnostics AB (publ) logo

Boule Diagnostics AB (publ)

BOUL.ST

9.36 SEK

Bio-Works Technologies AB (publ) logo

Bio-Works Technologies AB (publ)

BIOWKS.ST

4.85 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)